COMMUNIQUÉS West-GlobeNewswire

VIRBAC Announces Third Quarter 2025 Sales
16/10/2025
Sustained revenue growth at the end of September of +7.8% at constant exchange rates and scope Upgrade of the full-year revenue guidance Revenue growth now expected to be between 5.5% and 7.5% at constant rates and [...]
Press release: NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES ISSUANCE OF A NEW SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM
16/10/2025
Ghent, Oct. 16, 2025 (GLOBE NEWSWIRE) -- NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES ISSUANCE OF A NEW SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM Ghent, Belgium, 16 [...]
EssilorLuxottica: Chiffre d'affaires T3/9M 2025 - Chiffre d'affaires en hausse de 11,7 % au T3, meilleure performance trimestrielle du Groupe depuis sa création
16/10/2025
Chiffre d'affaires en hausse de 11,7 % au T3 Meilleure performance trimestrielle du Groupe depuis sa création Chiffre d'affaires T3 du Groupe à +11,7 % à taux de change constants 1 , +8,8 % sur les neuf premiers mois [...]
EssilorLuxottica: Q3/9M 2025 Revenue - Revenue up 11.7% in the third quarter, best quarterly performance ever for the Group
16/10/2025
Revenue up 11.7% in the third quarter Best quarterly performance ever for the Group Group’s revenue +11.7% in the third quarter at constant exchange rates 1 , +8.8% in the nine months Wearables major boost, enlarging [...]
ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 Meeting
16/10/2025
Presentation at AAO 2025 part of ongoing NEW DAY data dissemination at medical meetings PRINCETON, N.J., Oct. 16, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today [...]
Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor
16/10/2025
Patients treated with ulixacaltamide in the parallel-group study (Study 1) showed a mean improvement from baseline in the Modified Activities of Daily Living 11 at Week 8, the pre-specified primary endpoint, of 4.3 [...]
Ligand to Host Investor Day on December 9, 2025
16/10/2025
JUPITER, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take place in New York City on Tuesday, December 9, 2025 from 10:30 a [...]
BPGbio Presents Phase 2 Glioblastoma Data on BPM31510 at ESMO 2025
16/10/2025
BPGbio has completed phase 2b enrollment in late August this year for treatment of GBM with BPM31510 Data further validate the MOA of BPM31510’s direct targeting of mitochondrial redox machinery to re-potentiate [...]
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16/10/2025
WATERTOWN, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious [...]
Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit
16/10/2025
Foghorn to host a virtual investor event on updates for its Selective ARID1B, Selective CBP and Selective EP300 degrader programs on Thursday October 30, 2025, at 12 p.m. EDT CAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE [...]
Cellectis organise aujourd’hui son R&D Day pour présenter les avancées de son portefeuille et ses perspectives à long terme
16/10/2025
L’ensemble des données de phase 1 et la stratégie de l’essai clinique pivot de phase 2 pour le produit candidat lasmé-cel (UCART22) dans la LAL-B en rechute ou réfractaire, seront présentées durant l’événement NEW YORK [...]
Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers
16/10/2025
Event features full Phase 1 data and pivotal Phase 2 strategy for lasme-cel (UCART22) in r/r B-ALL NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a [...]
National PKU Alliance Grant Advances Engineered Native Bacteria Candidate for Phenylketonuria (PKU)
16/10/2025
San Diego, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Endure Biotherapeutics, Inc. (Endure Bio®), a pioneer in engineered engraftable microbial therapeutics, today announced that its founding discovery laboratory at the [...]
Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results
16/10/2025
Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 F, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will [...]
Gain Therapeutics to Attend the 2025 Maxim Growth Summit
16/10/2025
BETHESDA, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]
Verano Elevates Expanding Vape Product Portfolio with Exclusive, First-to-Market Launch of Revolutionary HYPHEN System
16/10/2025
HYPHEN features brand new best-in-class technology that allows consumers to flex between extracts, size formats and brands through interchangeable vape pods CHICAGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Verano Holdings [...]
Conavi Medical to Present at the Planet MicroCap Showcase: TORONTO in partnership with MicroCapClub on Wednesday, October 22, 2025
16/10/2025
TORONTO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing [...]
Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET
16/10/2025
CAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, [...]
Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases
16/10/2025
DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function Demonstrated [...]

Pages